Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
Huiying Gu, Jing Li, Nan You, et al.
Annals of Translational Medicine (2020) Vol. 8, Iss. 24, pp. 1677-1677
Open Access | Times Cited: 24

Showing 24 citing articles:

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
Lisha Mou, Xiaohe Tian, Bo Zhou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 52
Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
Weijun Wang, Zong‐Han Liu, Kang Wang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11513-11524
Open Access | Times Cited: 19
Recent advances in recurrent hepatocellular carcinoma therapy
Yuxue Gao, Qi-Qi Ning, Pengxiang Yang, et al.
World Journal of Hepatology (2023) Vol. 15, Iss. 4, pp. 460-476
Open Access | Times Cited: 17
Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway
Liang Xia, Mingjie Gong, Yang-fan Zou, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-15
Open Access | Times Cited: 25
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Kurzversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. 169-203
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Kurzversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. 293-336
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
Zhenzhen Zhang, Yanfang Wu, Tang‐Hui Zheng, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3710-3710
Open Access | Times Cited: 14
Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Di Pan, Haonan Liu, Pengfei Qu, et al.
Journal of Gastrointestinal and Liver Diseases (2024) Vol. 33, Iss. 1, pp. 85-93
Open Access | Times Cited: 2
Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients
Ningjie Li, Jiao Chen
Irish Journal of Medical Science (1971 -) (2022) Vol. 191, Iss. 6, pp. 2611-2617
Open Access | Times Cited: 8
What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis
Fuhai Hui, Chang Xu, Xiangbo Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma
Jing Liang, Yi Bai, Fushuang Ha, et al.
World Journal of Gastrointestinal Oncology (2023) Vol. 15, Iss. 1, pp. 1-18
Open Access | Times Cited: 4
Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Changlong Hou, Baizhu Xiong, Lei Zhou, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study
Hui Wang, Donghui Liu, Chu Wang, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 46, Iss. 6, pp. 101869-101869
Closed Access | Times Cited: 6
Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma
Ningjie Li, Ping Yang, Jun Fang
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 46, Iss. 9, pp. 102022-102022
Open Access | Times Cited: 6
Super‐Stable Homogeneously Sustained‐Release System Mediates Transcatheter Arterial Ionic‐Embolization Strategy for Hepatocellular Carcinoma Therapy
Xuqi Peng, Yating Zheng, Yi Xue, et al.
Advanced Functional Materials (2023) Vol. 34, Iss. 11
Closed Access | Times Cited: 2
Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Zhaonan Li, Quanjing Chen, Wenguang Zhang, et al.
Canadian Journal of Gastroenterology and Hepatology (2021) Vol. 2021, pp. 1-9
Open Access | Times Cited: 5
How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?
Yi Pan, Rui Chang, Zhonglin He, et al.
Medicine (2021) Vol. 100, Iss. 14, pp. e25360-e25360
Open Access | Times Cited: 4
Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C
Shuguang Ju, Wenhui Wang, Pengfei Chen, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 46, Iss. 3, pp. 101859-101859
Closed Access | Times Cited: 3
Non-surgical Treatment Options in Managing Recurrent Hepatocellular Carcinoma
Walaa Abdelhamed, Mohamed El‐Kassas
Gene Expression (2023) Vol. 22, Iss. 3, pp. 211-221
Open Access | Times Cited: 1
A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with DEB-TACE
Bo Jiang, Dong Lu, Jiaying Dai, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1403-1414
Open Access
Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study
Tao Ouyang, Junxia Liu, Chengyang Shi, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1459-1471
Open Access | Times Cited: 2
Apatinib plus drug-eluting bead transarterial chemoembolization as bridging therapy to surgical resection displays an acceptable efficacy and safety profile in hepatocellular carcinoma patients
Jingwei Yan, Yumei Sun, Daguang Fan, et al.
Indian Journal of Cancer (2023) Vol. 60, Iss. 4, pp. 562-569
Closed Access
Page 1

Scroll to top